Wealth Enhancement Trust Services’s AstraZeneca AZN Stock Holding History

Wealth Enhancement Trust Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27K	Buy	+12	New	+$2.26K	﹤0.01%	978

Other funds holding AZN

EPGL

Evelyn Partners Group Ltd London $46.9B AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Aviva London, United Kingdom $67.9B AUM 39.2% 1-Year Est. Return

Wealth Enhancement Trust Services's AZN Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in AstraZeneca (AZN) in Q2 2026: 12 shares worth $2.27K. The stake represents ﹤0.01% of the portfolio and ranks #978 among its holdings.

1,210 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Wealth Enhancement Trust Services held 12 shares of AstraZeneca worth $2.27K as of Q2 2026.
AstraZeneca was a new Wealth Enhancement Trust Services position in Q2 2026.
AstraZeneca made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #978 holding.
1,210 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.